DYOR. Analysis is highly-speculative. The analysis assumes RACE are successful in their strategy to prove up value of Zantrene in terms of clinical safety and efficacy for a range of cancer, camcer/cardio-protection and cardio-renal targets and then successfully achieve a commercial transaction. Potential outcomes include buyout, partnership or independent commercialisation.
Further to this, US-listed early-stage precision oncology companies are trading an a median market cap of USD $1.03B ( AUD $1.44B ) or around $8 per share fully-diluted.
RAC is significantly undervalued.
Here's a summary of my analysis with value indicators plotted on a chart - buyouts, partnerships, early-stage peers.
RAC is in a long-term uptrend. At the moment we have consolidation underway. I think this will eventually breakout (could take 4-5 months) for significant upside once the big seller runs out of stock.
DYOR. Analysis is highly-speculative. The analysis assumes RACE...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.040(2.42%) |
Mkt cap ! $267.8M | |||
| Open | High | Low | Value | Volume |
| $1.71 | $1.71 | $1.54 | $370.9K | 232.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 392 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.61 | 13999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.58 |
Change
-0.040 ( 6.08 %) |
||||
| Open | High | Low | Volume | ||
| $1.62 | $1.65 | $1.54 | 41933 | ||
| Last updated 15.58pm 15/05/2024 ? | |||||
| RAC (ASX) Chart |